C17orf80 Knockout cell line (ACHN)

Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.

Initiated in November 1979, ACHN is a well-established human cell line derived from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma. The cells were originally seeded directly into culture flasks in Eagle’s MEM supplemented with 10% FBS, and maintained through passages for 150 days before being inoculated subcutaneously into nude mice, where they formed palpable, locally invasive tumors within four weeks. Notably, both the parental ACHN cells and those recovered from the nude mouse tumors are distinctly growth-inhibited by human interferons, making ACHN a premier in vitro and in vivo model platform for investigating renal oncology progression, cytokine responses, and preclinical drug evaluation.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.